Literature DB >> 21621066

Developmental origins of fusion-negative rhabdomyosarcomas.

Ken Kikuchi1, Brian P Rubin, Charles Keller.   

Abstract

Rhabdomyosarcomas (RMS) are very heterogeneous tumors that can be divided into three major groups: alveolar rhabdomyosarcoma, embryonal rhabdomyosarcoma, and pleomorphic rhabdomyosarcoma. Concerted efforts over the past a decade have led to an understanding of the genetic underpinnings of many human tumors through genetically engineered models; however, left largely behind in this effort have been rare tumors with poorly understood chromosomal abnormalities including the vast majority of RMS lacking a pathognomonic translocation, i.e. fusion-negative RMS. In this chapter, we review the characteristic genetic abnormalities associated with human RMS and the genetically engineered animal models for these fusion-negative RMS. We explore not only how specific combinations of mutations and cell of origin give rise to different histologically and biologically distinguishable pediatric and adult RMS subtypes, but we also examine how tumor cell phenotype (and tumor "stem" cell phenotype) can vary markedly from the cell of origin.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21621066      PMCID: PMC6250435          DOI: 10.1016/B978-0-12-385940-2.00002-4

Source DB:  PubMed          Journal:  Curr Top Dev Biol        ISSN: 0070-2153            Impact factor:   4.897


  93 in total

1.  Detection of point mutations in N-ras and K-ras genes of human embryonal rhabdomyosarcomas using oligonucleotide probes and the polymerase chain reaction.

Authors:  M R Stratton; C Fisher; B A Gusterson; C S Cooper
Journal:  Cancer Res       Date:  1989-11-15       Impact factor: 12.701

Review 2.  Cancer stem cells: mirage or reality?

Authors:  Piyush B Gupta; Christine L Chaffer; Robert A Weinberg
Journal:  Nat Med       Date:  2009-09-04       Impact factor: 53.440

Review 3.  Hematologic masquerade of rhabdomyosarcoma.

Authors:  A A Sandberg; J F Stone; L Czarnecki; J D Cohen
Journal:  Am J Hematol       Date:  2001-09       Impact factor: 10.047

4.  Identification of a hypaxial somite enhancer element regulating Pax3 expression in migrating myoblasts and characterization of hypaxial muscle Cre transgenic mice.

Authors:  Christopher B Brown; Kurt A Engleka; Jennifer Wenning; Min Min Lu; Jonathan A Epstein
Journal:  Genesis       Date:  2005-04       Impact factor: 2.487

5.  P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines.

Authors:  A C Taylor; L Shu; M K Danks; C A Poquette; S Shetty; M J Thayer; P J Houghton; L C Harris
Journal:  Med Pediatr Oncol       Date:  2000-08

Review 6.  Understanding the cancer stem cell.

Authors:  S Bomken; K Fiser; O Heidenreich; J Vormoor
Journal:  Br J Cancer       Date:  2010-07-27       Impact factor: 7.640

7.  ErbB2 is required for muscle spindle and myoblast cell survival.

Authors:  Eran R Andrechek; William R Hardy; Adele A Girgis-Gabardo; Robert L S Perry; Richard Butler; Frank L Graham; Ronald C Kahn; Michael A Rudnicki; William J Muller
Journal:  Mol Cell Biol       Date:  2002-07       Impact factor: 4.272

8.  Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models.

Authors:  James G Taylor; Adam T Cheuk; Patricia S Tsang; Joon-Yong Chung; Young K Song; Krupa Desai; Yanlin Yu; Qing-Rong Chen; Kushal Shah; Victoria Youngblood; Jun Fang; Su Young Kim; Choh Yeung; Lee J Helman; Arnulfo Mendoza; Vu Ngo; Louis M Staudt; Jun S Wei; Chand Khanna; Daniel Catchpoole; Stephen J Qualman; Stephen M Hewitt; Glenn Merlino; Stephen J Chanock; Javed Khan
Journal:  J Clin Invest       Date:  2009-10-05       Impact factor: 14.808

9.  Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.

Authors:  Magali Olivier; David E Goldgar; Nayanta Sodha; Hiroko Ohgaki; Paul Kleihues; Pierre Hainaut; Rosalind A Eeles
Journal:  Cancer Res       Date:  2003-10-15       Impact factor: 12.701

10.  Pax3 and Pax7 have distinct and overlapping functions in adult muscle progenitor cells.

Authors:  Frédéric Relaix; Didier Montarras; Stéphane Zaffran; Barbara Gayraud-Morel; Didier Rocancourt; Shahragim Tajbakhsh; Ahmed Mansouri; Ana Cumano; Margaret Buckingham
Journal:  J Cell Biol       Date:  2005-12-27       Impact factor: 10.539

View more
  11 in total

1.  Induction of a regenerative microenvironment in skeletal muscle is sufficient to induce embryonal rhabdomyosarcoma in p53-deficient mice.

Authors:  Marybeth Camboni; Sue Hammond; Laura T Martin; Paul T Martin
Journal:  J Pathol       Date:  2011-10-18       Impact factor: 7.996

2.  Dystrophin and dysferlin double mutant mice: a novel model for rhabdomyosarcoma.

Authors:  Vishnu Hosur; Anoop Kavirayani; Jennifer Riefler; Lisa M B Carney; Bonnie Lyons; Bruce Gott; Gregory A Cox; Leonard D Shultz
Journal:  Cancer Genet       Date:  2012-05

3.  Genome-wide DNA methylation studies suggest distinct DNA methylation patterns in pediatric embryonal and alveolar rhabdomyosarcomas.

Authors:  Sarah E Mahoney; Zizhen Yao; C Chip Keyes; Stephen J Tapscott; Scott J Diede
Journal:  Epigenetics       Date:  2012-04-01       Impact factor: 4.528

4.  Congenital Orbital Rhabdomyosarcoma.

Authors:  Masoomeh Eghtedari; Amir Reza Farsiani; Mohammad Reza Bordbar
Journal:  Ocul Oncol Pathol       Date:  2017-11-04

5.  Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma.

Authors:  Timothy McKinnon; Rosemarie Venier; Marielle Yohe; Sivasish Sindiri; Berkley E Gryder; Jack F Shern; Leah Kabaroff; Brendan Dickson; Krista Schleicher; Guillaume Chouinard-Pelletier; Serena Menezes; Abha Gupta; Xiaohu Zhang; Rajarashi Guha; Marc Ferrer; Craig J Thomas; Yuhong Wei; Dariush Davani; Cynthia J Guidos; Javed Khan; Rebecca A Gladdy
Journal:  Oncogene       Date:  2018-02-28       Impact factor: 9.867

6.  Kras activation in p53-deficient myoblasts results in high-grade sarcoma formation with impaired myogenic differentiation.

Authors:  Timothy McKinnon; Rosemarie Venier; Brendan C Dickson; Leah Kabaroff; Manon Alkema; Li Chen; Jack F Shern; Marielle E Yohe; Javed Khan; Rebecca A Gladdy
Journal:  Oncotarget       Date:  2015-06-10

7.  Myogenic regulatory transcription factors regulate growth in rhabdomyosarcoma.

Authors:  Inês M Tenente; Madeline N Hayes; Myron S Ignatius; Karin McCarthy; Marielle Yohe; Sivasish Sindiri; Berkley Gryder; Mariana L Oliveira; Ashwin Ramakrishnan; Qin Tang; Eleanor Y Chen; G Petur Nielsen; Javed Khan; David M Langenau
Journal:  Elife       Date:  2017-01-12       Impact factor: 8.140

8.  Rhabdomyosarcoma and Wilms tumors contain a subpopulation of noggin producing, myogenic cells immunoreactive for lens beaded filament proteins.

Authors:  Jacquelyn Gerhart; Kathryn Behling; Michele Paessler; LaBraya Milton; Gregory Bramblett; Denise Garcia; Meghan Pitts; Reginald Hurtt; Mitchell Crawford; Richard Lackman; Daniela Nguyen; Joseph Infanti; Paul FitzGerald; Mindy George-Weinstein
Journal:  PLoS One       Date:  2019-04-11       Impact factor: 3.240

9.  Characteristic of Uterine Rhabdomyosarcoma by Algorithm of Potential Biomarkers for Uterine Mesenchymal Tumor.

Authors:  Saya Tamura; Takuma Hayashi; Tomoyuki Ichimura; Nobuo Yaegashi; Kaoru Abiko; Ikuo Konishi
Journal:  Curr Oncol       Date:  2022-03-28       Impact factor: 3.109

10.  Oncogenic role of HMGA2 in fusion-negative rhabdomyosarcoma cells.

Authors:  Kazutaka Ouchi; Mitsuru Miyachi; Shigeki Yagyu; Ken Kikuchi; Yasumichi Kuwahara; Kunihiko Tsuchiya; Tomoko Iehara; Hajime Hosoi
Journal:  Cancer Cell Int       Date:  2020-05-24       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.